

2019 #6

February 22, 2019

INSIDE:

CBER 2019 Guidance
Agenda.....3

April SMT Journal Club
Webinar Articles
Announced4

57th ABC Annual Meeting
Registration Open4

Registration Open for ABC
Quality and Technical
Workshop4

RESEARCH IN BRIEF5

RECENT REVIEWS6

BRIEFLY NOTED.....6

REGULATORY NEWS....6

MEMBER NEWS.....8

COMPANY NEWS8

STOPLIGHT®: Status of
America's Blood
Centers' Blood Supply .9

Upcoming ABC Webinars
– Don't Miss Out!.....10

ABC 2019 Meetings &
Workshops10

CALENDAR.....10

POSITIONS.....11

**ABC Annual Meeting to Address Blood Safety & Availability;
Regulatory Environment for Blood Centers**

America's Blood Centers' will hold its 57th Annual Meeting from March 23rd – 26th in Arlington, Va. at the Ritz-Carlton (Pentagon City). Featured speakers include U.S. Department of Health and Human Services (HHS) Assistant Secretary for Health Admiral Brett Giroir, MD, U.S. Food and Drug Administration Center for Biologics Evaluation and Research Director Peter Marks, MD, PhD, and Nancy Bocskor, director at the Center for Women in Politics & Public Policy at Texas Woman's University. This meeting provides an opportunity for ABC members to address regulators, legislators, industry partners and peers, while sharing best practices, networking, and keeping abreast of the latest trends impacting the blood community.

International Blood Safety Forum

Global Healing's International Blood Safety Forum (IBSF) will take place on Saturday March 23rd. Attendees will hear a keynote address from Bloodworks Northwest President and CEO James P. AuBuchon, MD, FCAP, FRCP(Edin), in addition to sessions on the benefits of how professional societies and the blood community assist with developing blood systems in low-resource countries. IBSF will conclude with a reception that evening.

General Session

Nancy Bocskor will kick off the general session of the ABC Annual Meeting on March 24th by presenting "Tell Me A Story: Touching Hearts, Winning Minds." She will share tips for crafting powerful messages and maximizing meetings with stakeholders.

The General Session will continue with Jarrard Inc. Founding Partner and Chief Innovation Officer Molly Cate discussing strategic positioning in the healthcare market. The morning will close with a look at the availability of donors to maintain a safe blood supply is continuous challenge for blood centers. William English, PhD and Peter Jaworski, PhD of Georgetown University will conclude the general session by examining the relationship and impact of paid plasma donation on unpaid blood donation.

SMT Forum & Celso Bianco Lectureship

The SMT Forum will begin on the afternoon of the March 24th with a presentation on O-negative use and management by Claudia Cohn, MD, PhD medical director of the University of Minnesota's Blood Bank Laboratory. Dr. Cohn will describe the appropriate uses of O-negative red blood cells (RBCs) and explain the overreliance on O-negative RBCs and potential solutions to address this issue.

(continued on page 2)



ABC 57th Annual Meeting (continued from page 1)

New York Blood Center Medical Director Patricia Shi, MD will discuss draft recommendations from ASH for sickle cell disease related transfusion support. Her presentation will include strategies to reduce RBC alloimmunization and hemolytic transfusion reactions and define management of iron overload. Richard Gammon, MD, medical director at OneBlood and Mary Townsend, MD, senior medical director in the national office of Vitalant will present white papers from ABC on mitigating teen donor reactions and the value of blood respectively. ABC Chief Medical Officer Louis Katz, MD will provide insights into emerging issues in transfusion medicine and discuss their operational impact on blood centers.

The SMT Forum will conclude with the Celso Bianco, MD Lectureship and a reception, open to all attendees celebrating the life of the late Dr. Bianco. Jay Epstein, MD, senior advisor for International Blood Regulatory Affairs in the FDA's CBER will give this year's lecture sharing the global efforts underway to strengthen national blood regulatory systems. He will share information to help the audience understand the role of regulation in assuring blood product quality, safety, efficacy, and availability.

Members Meeting & General Session & Advocacy Day

Monday, March 25th will begin with the ABC Members meeting and Bylaws hearing. The afternoon's General Session will feature Admiral Giroir providing attendees with a view from HHS and his perspective as the nation's Blood Safety Officer. Dara Alpert Lieberman, MPP, director of Government Relations at Trust for America's Health will discuss the current state of funding for public health and explain the priorities of the current administration and Congress related to preparedness and response.

The General Session will close with CBER's Peter Marks, MD, PhD addressing blood safety. Dr. Marks will describe the ability of new technologies to advance blood safety and availability, while addressing the role of regulatory agility in alleviating both safety and supply concerns. The evening will end with the 22nd Annual *Awards of Excellence*, which honors blood donation sponsors, corporations, and advocates who support the work community blood centers through their commitment to blood donation.

ABC Members will begin the final day of the meeting with a briefing on ABC's regulatory and legislative priorities during the Advocacy Forum before embarking for congressional visits on Capitol Hill. This is an opportunity for blood centers to advocate face-to-face with members of Congress. ABC will schedule visits and provide informational packets for all visits. Annual Meeting [registration](#) is open until March 22nd. Please make your hotel reservations by March 1st to ensure best availability and the group rate. Contact [Leslie Maundy](#) for available sponsorship opportunities. 💧

The *ABC Newsletter* (ISSN #1092-0412) is published by America's Blood Centers® and distributed by e-mail. Contents and views expressed are not official statements of ABC or its Board of Directors. Copyright 2019 by America's Blood Centers. Reproduction of the *ABC Newsletter* is forbidden unless permission is granted by the publisher. (ABC members need not obtain prior permission if proper credit is given.)

ABC advocates for and advances policies that promote the role of independent blood centers in providing life-saving blood products and recognize the continuous need for a safe and robust blood supply. ABC exists to advocate for laws and regulations recognizing the essential role that independent blood centers play in the healthcare system; promote partnerships, policies and programs that increase awareness about the need for blood donation; and serve as a thought-leader in the advancement of evidence-based medical and scientific solutions related to health and safety.

America's Blood Centers

Chief Executive Officer: Kate Fry

Chief Medical Officer: Louis Katz

Editor: Mack Benton

Subscriptions Manager: Leslie Maundy

Annual Subscription Rate: \$390

Send subscription queries to

lmaundy@americasblood.org

America's Blood Centers

1717 K St. NW, Suite 900, Washington, DC 20006

Phone: (202) 393-5725

Send news tips to newsletter@americasblood.org.



CBER 2019 Guidance Agenda

The U.S. Food and Drug Administration's (FDA) Center for Biologics Evaluation and Research (CBER) has [published](#) its guidance calendar for 2019. The agenda outlines the guidance and draft guidance documents that CBER plans to issue throughout the year. Topics of note that the agency will look to address include:

- Implementation of Pathogen Reduction Technology in the Manufacture of Blood Components in Blood Establishments: Questions and Answers; Guidance for Industry;
- Revised Preventive Measures to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease (CJD) and Variant Creutzfeldt-Jakob Disease (vCJD) by Blood and Blood Products; Draft Guidance for Industry;
- Considerations for the Development of Dried Plasma Products Intended for Transfusion; Guidance for Industry; and
- Bacterial Risk Control Strategies for Blood Collection Establishments and Transfusion Services to Enhance the Safety and Availability of Platelets for Transfusion; Guidance for Industry.

A complete listing of the potential guidances is available on the FDA's [website](#).

(Source: FDA [Announcement](#), 2/20/19) ♦

AMERICA'S BLOOD CENTERS'

57TH

ANNUAL MEETING

March 23-26, 2019 | Washington, DC



2019 ANNUAL MEETING SCHEDULE

Saturday, March 23: International Blood Safety Forum
ABC Board Meeting

Sunday, March 24: General Session
SMT Forum & Celso Bianco Lectureship
Celso Bianco Celebration of Life Reception

Monday, March 25: ABC Members Meeting
General Session
22nd Annual Awards of Excellence

Tuesday, March 26: Advocacy Forum
Capitol Hill Visits

“ The ABC Annual Meeting is the premiere opportunity for individuals to explore trends amongst peers within the blood community, contribute their thoughts and ideas to important policy discussions with regulators, while sharing their stories with legislators and networking with industry partners. Value exists for professionals of all experience levels. Join us in Washington, D.C.!”

*—Kate Fry, Chief Executive Officer
America's Blood Centers*



America's Blood Centers®
It's About Life.



Hotel Information
Ritz-Carlton (Pentagon City)
Hotel room rate: \$259



For registration information, visit http://bit.ly/abc_am19.

For sponsorship opportunities, please contact Leslie Maundy at Imaundy@americasblood.org.

We Welcome Your Letters

The *ABC Newsletter* welcomes letters from its readers on any blood-related topic that might be of interest to ABC members. Letters should be kept relatively short and to the point, preferably about a topic that has recently been covered in the *ABC Newsletter*. Letters are subject to editing for brevity and good taste and published after editorial review. Please send letters to the Editor at newsletter@americasblood.org or fax them to (202) 899-2621. Please include your correct title and organization as well as your phone number. The deadline for letters is Wednesday to make it into the next newsletter.



America's Blood Centers®
It's About *Life*.

INSIDE ABC

The programs and services described in the Inside ABC section are available to ABC member blood centers and their staff only, unless otherwise specified.

April SMT Journal Club Webinar Articles Announced

The ABC Scientific, Medical, and Technical (SMT) Journal Club Webinar on April 3rd at noon eastern will feature the articles below:

- Older Blood Is Associated with Increased Mortality and Adverse Events in Massively Transfused Trauma Patients: Secondary Analysis of the PROPPR Trial (*Annals of Emergency Medicine*);
- Bombay Phenotype (O_h) and High-titer Anti-H in Pregnancy: Two Case Reports and a Review of the Literature (*Transfusion*); and
- Elevated Risk for Iron Depletion in High-School Age Blood Donors (*Transfusion*).

Additional details including registration information is forthcoming.

(Source: ABC Webinar [Announcement](#), 2/19/19)

57th ABC Annual Meeting Registration Open

[Registration](#) is open for America's Blood Centers' (ABC) 57th Annual Meeting in Washington, D.C. March 23rd – 26th, 2019 at the Ritz-Carlton (Pentagon City). Don't miss an exclusive opportunity for blood center leaders to experience peer-to-peer collaboration, while discussing the latest trends impacting community blood centers. The meeting will feature the Celso Bianco, MD Lectureship & Celebration of Life Reception, the Scientific, Medical, and Technical Forum, Capitol Hill Visits, General Session, and the 22nd Annual *Awards of Excellence*. Please make your hotel [reservations](#) by March 1st to ensure best availability and the group rate. Click [here](#) for additional details. Contact [Leslie Maundy](#) for available [sponsorship](#) opportunities.



Registration Open for ABC Quality and Technical Workshop

[Register](#) today to take advantage of early bird discounts rates available through February 25th for the ABC Quality and Technical Workshop in Bloomington, Minn. at the Embassy Suites Bloomington. [Reserve](#) your room by April 5th to secure the group rate of \$139. This year, ABC and Blood Centers of America, Inc. (BCA) are partnering to provide a multiday professional development and educational opportunity for quality and technical blood bank professionals. The BCA IRL Networking Conference/IRL Disease Symposium will take place on April 29-30th with the ABC Quality (QA) & Technical Directors (TD) Workshops following it on April 30th- May 2nd. Additional schedule and registration information are below:

- April 29: BCA IRL Networking Conference (*BCA members-only; BCA will provide registration information*)
- April 30: BCA IRL Disease Symposium (*All ABC members welcome; no registration fee; ABC will provide symposium registration*)
- April 30 – May 1: TD Workshop and Joint TD/QA Session
- May 2: QA Workshop

(continued on page 5)



INSIDE ABC (continued from page 4)

Registration & Fees:

- Breakfast, lunch, and two receptions included.
- ABC QA/TD Workshop Registration Fees: (Early Bird: mid-Feb-Feb 23/Regular: Feb 24-April 5)
 - TD or QA Workshop: \$360 early bird/\$420 regular
 - TD & QA Workshop: \$435 early bird/\$495 regular

RESEARCH IN BRIEF

Use of riboflavin and ultraviolet (UV) pathogen reduced red blood cells (RBCs) in pediatric hematology oncology patients.

A single center, single-blind, randomized study from Russia included 70 children (0.3-17 years old). Half with cancer received RBCs from treated whole blood and the other half were transfused with gamma irradiated, standard RBCs. Hemoglobin increments, transfusion requirements, and transfusion reactions were the clinical endpoints. Eleven *in vitro* analytes were measured to assess changes in the “quality” of treated and control components out to 21-days of storage. Post-transfusion hemoglobin and hematocrit levels were statistically indistinguishable between the two groups, as was the interval between transfusions. Reaction rates from transfusion were not influenced by the RBCs used. The expected statistically significant changes in biochemical tests were seen, but none appeared likely to be of clinical importance.

Citation: Trakhtman, P., Kumakova, I., Starostin, N., *et al.* The pathogen-reduced red blood cell suspension: single centre study of clinical safety and efficacy in children with oncological and haematological diseases. *Vox Sang.* 2019. doi: [10.1111/vox.12757](https://doi.org/10.1111/vox.12757).

Gender and age at onset of myasthenia gravis (MG) are associated with the response to plasma exchange, but not autoantibody status. Blood centers are frequently asked to consider performing therapeutic apheresis on patients with MG. This retrospective case series from Texas included 58 consecutive MG patients treated with plasma exchange from 2015 to 2017. Comparisons studied in the univariate analysis included demographics, age at onset, the autoantibody status (44 with anti-acetyl choline receptor, seven with anti-MuSK, and seven with none), the presence of thymoma, and the use of thymectomy. The overall response rate was 96% with only male gender and late onset associated with the treatment response.

Citation: Usmani, A., Kwan, L., Wahib-Khalil, D., *et al.* [Excellent response to therapeutic plasma exchange in myasthenia gravis patients irrespective of antibody status.](#) *J. Clin. Apheresis.* 2019.

Peripheral blood stem cell (PBSC) transplantation for relapsing-remitting multiple sclerosis (MS).

MS is an autoimmune disease characterized by loss of tolerance to antigenic components of the central nervous system. The relapsing-remitting form results in irreversible, progressive neurological morbidity in the majority of patients. Stability is seen on the best current therapy after four years in <20 percent of patients. Nine hundred twenty-six MS patients were screened for eligibility for a multicenter, controlled trial comparing transplant with pharmacologic disease modifying treatment (DMT) for patients already receiving DMT who had least two relapses during the prior year. Fifty-five patients were randomized to PBSC transplantation and 55 to a more efficacious or a different DMT. Disease progression was seen in three transplant patients compared to 34 DMT enrollees. Due to the small study size, it is considered preliminary. Also, DMT patients were allowed to cross over to transplant so long-term comparisons will be limited, some contemporary (possibly more effective) DMT agents were not available to the cohort and

(continued on page 6)

RESEARCH IN BRIEF (continued from page 5)

some assessments were not blinded. The authors conclude that “further research is needed to replicate these findings and to assess long-term outcomes and safety.”

Citation: Burt, B.K., Balabanov, R., Burman J., *et al.* Effect of nonmyeloablative hematopoietic stem cell transplantation vs continued disease-modifying therapy on disease progression in patients with relapsing-remitting multiple sclerosis a randomized clinical trial. *JAMA*. 2019. doi: [10.1001/jama.2018.18743](https://doi.org/10.1001/jama.2018.18743). ♦

RECENT REVIEWS

How to Assess and Treat Low Levels of von Willebrand factor (vWF). Irish authors use a case study format to discuss the classification of patients with low vWF, their clinical phenotypes, and their approach to treatment decisions. They concentrate on clinical and laboratory diagnosis, the rational assessment of bleeding history, perioperative assessment and management, and obstetric issues. The authors conclude with their list of subjects for further research.

Citation: Lavin, M. and O'Donnell, J.S. [How I treat low von Willebrand factor levels](#). *Blood*. 2019. ♦

BRIEFLY NOTED

The World Health Organization has created an 18-member committee to establish guidelines for human gene editing. In a [report](#) from the *Wall Street Journal*, the committee will “examine the scientific, ethical, social and legal challenges associated with editing human genes and it will make recommendations...Core to their work will be understanding how to promote transparency and accountability within the scientific community, as well as what risk assessments should be made before sign-offs are granted on such experiments.” The group will meet in Geneva, Switzerland in March. This comes in the wake of the controversy surrounding a scientist in China who edited the genes of human embryos in hopes of making them HIV-resistant resulting in the births of gene-edited twins.

(*Wall Street Journal*, [WHO Reacts to Chinese Gene-Edited Twins with Plan for Global Guidelines](#), 2/21/19) ♦

REGULATORY NEWS

The U.S. Food and Drug Administration (FDA) has [warned](#) the public about the claims by establishments that offer plasma infusions from young human donors to treat aging and ailments such as dementia and Parkinson's disease. Several establishments had opened around the U.S. marketing the supposed benefits of young plasma infusions, which concerned the agency. In a joint [statement](#) released on Tuesday (February 19th) from FDA Commissioner Scott Gottlieb, MD and director of FDA's Center for Biologics Evaluation and Research (CBER) Peter Marks, MD, PhD, the FDA said “[t]here is no proven clinical benefit of infusion of plasma from young donors to cure, mitigate, treat, or prevent these conditions, and there are risks associated with the use of any plasma product...Our concerns regarding treatments using plasma from young donors are heightened by the fact that there is no compelling clinical evidence on its efficacy, nor is there information on appropriate dosing for treatment of the conditions for which these products are being advertised. Plasma is not FDA-recognized or approved to treat conditions such as normal aging or memory loss, or other diseases like Alzheimer's or Parkinson's disease. Moreover, reports we're seeing indicate that the dosing of these infusions can involve administration of large volumes of plasma

(continued on page 7)



REGULATORY NEWS (continued from page 6)

that can be associated with significant risks including infectious, allergic, respiratory and cardiovascular risks, among others.”

(Source: FDA [Advisory](#), 2/19/19; Scott Gottlieb, MD & Peter Marks, MD, PhD Joint [Statement](#), 2/19/19)

The Centers for Medicare & Medicaid Services (CMS) has [proposed](#) national health coverage for FDA-approved chimeric antigen receptor (CAR) T-cell therapy “under Coverage with Evidence Development CED”. “CAR T-cell therapy was the first FDA-approved gene therapy, marking the beginning of an entirely new approach to treating serious and even life-threatening diseases,” said CMS Administrator Seema Verma in an agency news release. “Today’s proposed coverage decision would improve access to this therapy while deepening CMS’s understanding of how patients in Medicare respond to it, so the agency can ensure that it is paying for CAR T-cell therapy for cases in which the benefits outweigh the risks.” The proposal would provide national Medicare coverage for CAR-T-cell therapy if it is “offered in a CMS-approved registry or clinical study, in which patients are monitored for at least two years post-treatment.” CMS is seeking comments on the proposal until March 17, 2019. More information including the comment submission portal is available [here](#).

(Source: CMS News [Release](#), 2/15/19) ♦

AMERICA'S BLOOD CENTERS'

TECHNICAL AND QUALITY WORKSHOP

Bloomington, MN | April 30 - May 2, 2019





HOTEL INFORMATION:
Embassy Suites Bloomington:
Hotel room rate: \$139

2019 WORKSHOP SCHEDULE

BCA IRL Disease Symposium: April 30
 Technical: April 30-May 1
 Joint Technical & Quality: May 1
 Quality: May 2

Hosted by:



INNOVATIVE BLOOD RESOURCES




America's Blood Centers®
It's About Life.

2019 WORKSHOP FEES
(EARLY BIRD/REGULAR)

TD or QA: \$360/\$420
TD and QA: \$435/\$495

*Registration for Technical or Quality includes the Joint Session.

For registration information, visit http://bit.ly/abc_tq19.

Sponsorship opportunities available. Contact Leslie Maundy at Imaundy@americasblood.org for details.

“ ABC is proud to partner with BCA to offer this multi-day educational event for quality and technical blood bank professionals. We hope you will join us for this unique opportunity to learn, collaborate and network with your colleagues from across the industry. ”
– Kate Fry, MBA, CEO, America’s Blood Centers





MEMBER NEWS

Vitalant's Blood Science Foundation will recognize Chicago-area youth as a part of The NextUp Awards. According to a news [release](#) from the foundation, the program will provide \$2,500 scholarships to three individuals “who have shown a transformative commitment to their communities – through fundraising, the development of charitable programs, volunteering, leadership and philanthropy” An awards ceremony announcing the recipients will take place on March 12th. “The very best of our youngest generation is taking ownership of their futures,” said Blood Science Foundation President and Chief Financial Officer Mark Giaquinto, in the news release. “They realize it's about the good they can do for others, which can create a ripple effect and set an example for the entire region.” Blood Science Foundation Board Member Sunny Chico added, “[t]hroughout Chicago, determined young people are looking beyond themselves and doing good in their communities. At Blood Science Foundation, we believe it is vital to give them the recognition that they deserve. That's why we launched the NextUp Awards.”



(Source: Blood Science Foundation News [Release](#), 2/19/19)



Stanford Blood Center recently held a ribbon-cutting ceremony to celebrate the grand opening of a new donor center in Campbell, Calif. on January 31st. “We designed the new center from the ground up with our donors in mind, helping to create a comfortable experience in a modern, relaxing environment. We want to ensure that every donor has the best donation experience possible,” said Stanford Blood Center Executive Director Harpreet Sandhu, MBA in a news [release](#). Both community members and leaders celebrated the opening, which include former Campbell Mayor Paul Resnikoff.

(Source: Stanford Blood Center News [Release](#), 1/31/19) 💧

COMPANY NEWS

Be The Match BioTherapies® and **Gamida Cell, Ltd.** announced a partnership with a focus on the NiCord® program, Gamida Cell's investigational cell therapy which aims to potentially be a universal bone marrow donor source for transplant patients and individuals suffering from blood cancers. “Gamida Cell's work to bring a new therapeutic option to patients in need of a bone marrow transplant aligns with our core mission to help organizations deliver cellular therapies that save more lives and improve the quality of life for patients,” said Be The Match BioTherapies President Amy Ronneberg in a news release. “This collaboration is designed to leverage our expertise in cellular therapy to support the advancement of Gamida Cell's clinical development and product delivery efforts.” Through the shared synergies, the organizations aim to improve patient outcomes for hematopoietic stem cell transplantation patients. “Be the Match BioTherapies is a respected leader in cell therapy, with especially deep roots in stem cell transplantation,” said


(continued on page 9)

COMPANY NEWS (continued on page 8)


Gamida Cell CEO Julian Adams in the joint news release. “Our two organizations share the belief that new cell therapies are needed not only to improve outcomes for patients undergoing stem cell transplants but also to offer patients unable to find a matched donor the chance for a successful transplant. This collaboration maximizes the strengths and expertise of our teams to help move us closer to our common goal of transforming this important area of medicine.”

(Source: Gamida Cell and Be The Match BioTherapies Joint [Release](#), 1/22/19) 💧

STOPLIGHT®: Status of America’s Blood Centers’ Blood Supply



The order of the bars is (from top to bottom), red, yellow, green, and no response



Daily updates are available at:
www.AmericasBlood.org

ABC Calendar of Events

ABC offers a variety of meetings, workshops and virtual opportunities for education and networking as well as participation in ABC business. The [calendar of events](#) includes annual and summer meetings, board meetings, workshops, and webinars, and details will be updated as confirmed. We look forward to your support and participation!



ABC 2019 Meetings & Workshops				
Meeting/Workshop	Dates	Location	Hotel/Hotel Rate	Registration Dates & Fees
Annual Meeting	March 23-26	Washington, DC	Ritz-Carlton (Pentagon City), \$259/night	Register here by Mar. 1 \$760
Technical & Quality Workshop	April 30-May 2	Bloomington, Minnesota	Embassy Suites, \$139/night	Mid-Feb. (Early Bird TD or QA or TD + QA) \$360/\$435; Feb. 25-Apr. 5 (TD or QA or TD + QA) \$420/\$495
ADRP Annual Conference	May 14-16	Indianapolis, Indiana	Hyatt Regency, \$179/night	Register here now Subscribers \$575/\$695 non-subscribers
Medical Directors Workshop	July 30 (precedes Summer Mtg)	Denver, Colorado	Grand Hyatt, \$239/night	Late April - July 5 MD Workshop \$435 MD+Summer \$760
Summer Meeting	July 31-August 1	Denver, Colorado	Grand Hyatt, \$239/night	Late April - July 5 Summer \$655 Summer+MD \$760
Notes: For the most up-to-date information on all events, members of ABC may check the calendar on ABC's Member Site. Non-members may attend all events; information will be updated on ABC's Public Site .				

Upcoming ABC Webinars – Don't Miss Out!

- **ABC Bylaws Webinar** – March 8th. Additional details forthcoming!
- **ADRP Webinar - Diversification of the Donor Pool: Identifying Challenges and Highlighting Strategies for Successful Donor Recruitment and Retention** – March 14th – [Register](#) today!
- **SMT Journal Club** – April 3rd. Additional details forthcoming!
- **QA Education Webinar – PRT & Double Red Cell Licensure** – April 9th. Additional details forthcoming!
- **QA Education Webinar – Change Management** – July 16th. Additional details forthcoming!

CALENDAR

Note to subscribers: Submissions for a free listing in this calendar are welcome. Send information to Leslie Maundy by e-mail (lmaundy@americasblood.org) or by fax to (202) 899-2621. (For a more detailed announcement in the weekly "Meetings" section of the newsletter, please include program information.)

2019

March 6-7. **IPFA 4th Asia Workshop on Plasma Quality and Supply, Hanoi, Vietnam.** More details available [here](#).

March 7. **22nd U.S.-Japan Cellular and Gene Therapy Conference, Silver Spring, MD.** More details available [here](#).

(continued on page 11)



CALENDAR (continued from page 10)

March 20-21. **FDA Blood Products Advisory Committee Meeting, Silver Spring, MD.** More details available [here](#).

March 23. **2019 International Blood Safety Forum, Washington, D.C.** More details available [here](#).

March 24-26. **2019 ABC Annual Meeting, Washington, D.C.** More details available [here](#).

April 23-24. **15th Annual FDA and the Changing Paradigm for HCT/P Regulation, Washington, D.C.** More details available [here](#).

April 30-May 2. **2019 ABC Technical & Quality Workshop, Minneapolis, Minn.** More details available [here](#).

May 14-16. **ADRP Annual Conference, Indianapolis, Ind.** More details available [here](#).

May 22-23. **IPFA/PEI 26th International Workshop on “Surveillance and Screening of Blood-Borne Pathogens”, Krakow, Poland.** More details available [here](#).

July 30-Aug. 1. **2019 ABC Medical Directors Workshop & Summer Meeting, Denver, Colo.** More details coming soon.



CLASSIFIED ADVERTISING

Classified advertisements, including notices of positions available and wanted, are published free of charge for a maximum of three weeks per position per calendar year for ABC institutional members. There are charges for non-members: \$139 per placement for *ABC Newsletter* subscribers and \$279 for non-subscribers. A six (6) percent processing fee will be applied to all credit card payments. Notices ordinarily are limited to 150 words. To place an ad, contact Leslie Maundy at the ABC office. Phone: (202) 654-2917; fax: (202) 899-2621; e-mail: lmaundy@americasblood.org.

POSITIONS

Chief Medical Officer (America’s Blood Centers). Reporting to the Chief Executive Officer (CEO), the Chief Medical Officer (CMO) is responsible for implementing strategies and tactics, consistent with the best scientific and medical evidence and regulatory requirements, that support America’s Blood Centers’ (ABC) mission, maintain our values, and realize our vision. The CMO works as part of the ABC Senior Executive Team (SET) to communicate ABC’s issues to members, regulators, legislators, and external groups and mobilizes ABC members and professional staff to achieve the strategic goals of the organization. The CMO serves as a public advocate for ABC, maximizing the organization’s public presence as a national leader in shaping the future of blood banking, transfusion medicine, and cell therapies. Responsibilities: Represent independent non-profit community blood centers on scientific, medical, and technical matters as well as donor and patient safety concerns before federal agencies, industry and other business partners, allied domestic and international organizations, scientific societies, the media, and the public. Advise the

CEO, ABC Board of Directors, and ABC member centers on medical, scientific, technical, safety, and policy issues germane to blood banking. Stay apprised of pertinent regulatory developments and develop effective strategies to achieve success on regulatory issues affecting ABC

members. Education & Experience: Medical Degree required. U.S. medical license required with board certification in a medical specialty. Board certification in pathology, transfusion medicine, hematology, or infectious disease preferred. Ten or more years’ experience related to blood banking or transfusion medicine. Three or more years’ experience with healthcare and/or blood banking issues at a national level via committee work, offices held, or other appropriate experience. Administrative experience in a leadership role preferred. Please click [here](#) to view the full job description. To apply, please submit a resume and cover letter to [Kate Fry](#). Applications must be received by March 1st.

Immunohematology Reference Laboratory Assistant Director (Hoxworth Blood Center). The ideal candidate will have five years’ experience and SBB (ASCP) at the supervisor level or above in the areas of immunohematology reference testing and/or transfusion service. The Assistant Director is responsible for providing leadership, expertise and oversight with emphasis on customer interactions with our 24 hour associated labs and regional transfusion services, coordinating development, training, and managing resources. The Assistant Director assures that departmental processes, procedures,

(continued on page 12)

POSITIONS (continued from page 11)

and quality control activities are compliant with accreditation and regulatory standards. Successful candidate will be responsible for all testing, technical operation, and standard supervisory functions. Other duties include developing/managing contracts and bids, budget development and management, management of a licensed regional antibody registry, relevant projects, training and education of selected transfusion service technologists, bachelors/masters' students and post-doctoral physicians/scientists. Apply – Req ID #35809 <https://www.uc.edu/hr/careers.html>

ORISE Fellow (Blood, Tissue, and Tick-Borne Disease Fellowship, Office of HIV/AIDS and Infectious Disease, Office of the Assistant Secretary for Health, U.S. Department of Health and Human Services, Washington D.C. -- DHHS-OASH-2012-0010). A research and health policy opportunity is available in the Office of HIV/AIDS and Infectious Disease within the Office of the Assistant Secretary for Health (OASH) of the U.S. Department of Health and Human Services (DHHS). The selected participant will assist with program management for research projects currently underway within the division relating to U.S. blood, tissue safety and availability, and tick-borne diseases. Opportunities may include: Project management for studies looking at topics relating to blood and tissue collection and utilization, transfusion-transmissible infections in blood donors, and infectious disease markers in potential organ and tissue donors. The Research Participation Program for DHHS is administered by the Oak Ridge Institute for Science and Education (ORISE). The initial appointment is for one year but may be renewed upon recommendation of OASH contingent on the availability of funds and project needs. The participant will receive a monthly stipend based on educational level and experience. Qualifications: A master's degree in public health, knowledge of the regulatory requirements for blood and tissue transplantation and knowledge of tick-borne diseases. Click [here](#) to view the full job description. To be considered, send a current CV/resume to the attention of [Tasha Powell](#). Please reference DHHS-OASH-2012-0010 in all communications.

Director of Quality Assurance (Central California Blood Center). CCBC (Fresno, California) seeks a Director of Quality Assurance. This critical leadership position reports to the President and CEO and leads the QA department. Responsibilities include assuring that all operational processes and practices are in compliance with FDA, CLIA, State, OSHA and EU regulations, as well as AABB standards and all customer specifications. Collaborates with peers in the senior management team to maintain a safe environment for blood donors and the purity and potency of blood and biological products. Responsible for planning and conducting scheduled and unannounced departmental audits. Shall partner with internal and external experts to upgrade our occurrence management process from paper to electronic. Shall maintain a robust quality management program consistent with cGMP. Shall be expected to actively educate and mentor key department and operations leaders in quality theory and practice. Requirements include at least 3 years of department leadership experience in a clinical setting, BS with MT(ASCP) and excellent oral and written communication and collaboration skills; MS with quality certifications, SBB preferred. Competitive salary and benefits, PTO holidays, matching 401(k) plan. Relocation allowance provided. Considering relocating to the Central Valley of California? Fresno is ideally located within a couple hours' drive to Yosemite National Park, Paso Robles wine region, California's Central Coast and the San Francisco Bay area. The Central California Blood Center is committed to saving lives and improving patient care by providing a safe and abundant blood supply for the patients and families in the communities we serve. Together life flows from here. For more information visit www.DonateBlood.org. ♦